Literature DB >> 19447902

The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy.

Shu Zhang1, Ping Lei, Xinyi Liu, Xiangrong Li, Kelcey Walker, Leela Kotha, Craig Rowlands, Stephen Safe.   

Abstract

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and the relatively non-toxic selective aryl hydrocarbon receptor (AhR) modulator 6-methyl-1,3,8-trichlorodibenzo-furan (MCDF) induced CYP1A1-dependent ethoxyresorufin O-deethylase activity and inhibited proliferation of seven estrogen receptor (ER) negative breast cancer cell lines. MCDF, TCDD and structurally related 2,3,7,8-tetrachlorodibenzofuran, 1,2,3,7,8-pentachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 3,3',4,4',5-pentachlorobiphenyl induced CYP1A1 and inhibited proliferation of BT-474 and MDA-MB-468 cells. In BT474 and MDA-MB-468 cells transfected with a small inhibitory RNA for the AhR, the antiproliferative activity of the chlorinated aromatic compounds was reversed, whereas for MCDF, only partial reversal was observed, suggesting that this compound acts through both AhR-dependent and AhR-independent pathways in these two cell lines. MCDF also inhibited tumor growth in athymic nude mice in which MDA-MB-468 cells were injected directly into the mammary fat pad. These results suggest that the AhR is a potential drug target for treatment of ER-negative breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447902      PMCID: PMC2766348          DOI: 10.1677/ERC-09-0054

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  43 in total

1.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

2.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

3.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.

Authors:  Anthony Howell; John Pippen; Richard M Elledge; Louis Mauriac; Ignace Vergote; Stephen E Jones; Steven E Come; C Kent Osborne; John F R Robertson
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

4.  Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review).

Authors:  Stephen Safe; Andrew McDougal
Journal:  Int J Oncol       Date:  2002-06       Impact factor: 5.650

5.  Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells.

Authors:  E Castro-Rivera; M Wormke; S Safe
Journal:  Mol Cell Endocrinol       Date:  1999-04-25       Impact factor: 4.102

6.  Partial antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated induction of aryl hydrocarbon hydroxylase by 6-methyl-1,3,8-trichlorodibenzofuran: mechanistic studies.

Authors:  M Harris; T Zacharewski; B Astroff; S Safe
Journal:  Mol Pharmacol       Date:  1989-05       Impact factor: 4.436

7.  The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes.

Authors:  Mark Wormke; Matthew Stoner; Bradley Saville; Kelcey Walker; Maen Abdelrahim; Robert Burghardt; Stephen Safe
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

8.  Mechanism of action of 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonists: characterization of 6-[125I]methyl-8-iodo-1,3-dichlorodibenzofuran-Ah receptor complexes.

Authors:  J Piskorska-Pliszczynska; B Astroff; T Zacharewski; M Harris; R Rosengren; V Morrison; L Safe; S Safe
Journal:  Arch Biochem Biophys       Date:  1991-01       Impact factor: 4.013

9.  Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor.

Authors:  Francisco J Quintana; Alexandre S Basso; Antonio H Iglesias; Thomas Korn; Mauricio F Farez; Estelle Bettelli; Mario Caccamo; Mohamed Oukka; Howard L Weiner
Journal:  Nature       Date:  2008-03-23       Impact factor: 49.962

10.  The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins.

Authors:  Marc Veldhoen; Keiji Hirota; Astrid M Westendorf; Jan Buer; Laure Dumoutier; Jean-Christophe Renauld; Brigitta Stockinger
Journal:  Nature       Date:  2008-03-23       Impact factor: 49.962

View more
  35 in total

1.  Aryl hydrocarbon receptor activation during pregnancy, and in adult nulliparous mice, delays the subsequent development of DMBA-induced mammary tumors.

Authors:  Tao Wang; Heather M Gavin; Volker M Arlt; B Paige Lawrence; Suzanne E Fenton; Daniel Medina; Beth A Vorderstrasse
Journal:  Int J Cancer       Date:  2010-06-02       Impact factor: 7.396

2.  In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo.

Authors:  Ashley J Parks; Michael P Pollastri; Mark E Hahn; Elizabeth A Stanford; Olga Novikov; Diana G Franks; Sarah E Haigh; Supraja Narasimhan; Trent D Ashton; Timothy G Hopper; Dmytro Kozakov; Dimitri Beglov; Sandor Vajda; Jennifer J Schlezinger; David H Sherr
Journal:  Mol Pharmacol       Date:  2014-08-26       Impact factor: 4.436

Review 3.  Aryl hydrocarbon receptor ligands in cancer: friend and foe.

Authors:  Iain A Murray; Andrew D Patterson; Gary H Perdew
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

4.  Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer.

Authors:  Tao Wang; Katie L Wyrick; Gary G Meadows; Tamara B Wills; Beth A Vorderstrasse
Journal:  Toxicol Sci       Date:  2011-09-26       Impact factor: 4.849

5.  Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human Breast Cancer Cells.

Authors:  Lancelot S McLean; Cheri N Watkins; Petreena Campbell; Dain Zylstra; Leah Rowland; Louisa H Amis; Lia Scott; Crystal E Babb; W Joel Livingston; Agus Darwanto; Willie L Davis; Maheswari Senthil; Lawrence C Sowers; Eileen Brantley
Journal:  Chem Res Toxicol       Date:  2015-04-01       Impact factor: 3.739

6.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits human ovarian cancer cell proliferation.

Authors:  Yan Li; Kai Wang; Yi-Zhou Jiang; Xin-Wen Chang; Cai-Feng Dai; Jing Zheng
Journal:  Cell Oncol (Dordr)       Date:  2014-11-18       Impact factor: 6.730

7.  Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.

Authors:  Shu Zhang; KyoungHyun Kim; Un Ho Jin; Catherine Pfent; Huojun Cao; Brad Amendt; Xinyi Liu; Heather Wilson-Robles; Stephen Safe
Journal:  Mol Cancer Ther       Date:  2011-10-27       Impact factor: 6.261

8.  Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death.

Authors:  Leah K Rowland; Petreena S Campbell; Nicole Mavingire; Jonathan V Wooten; Lancelot McLean; Dain Zylstra; Gabriell Thorne; Devin Daly; Kristopher Boyle; Sonya Whang; Juli Unternaehrer; Eileen J Brantley
Journal:  J Cell Biochem       Date:  2018-11-18       Impact factor: 4.429

9.  A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention.

Authors:  Nina Korzeniewski; Sarah Wheeler; Payel Chatterjee; Anette Duensing; Stefan Duensing
Journal:  Mol Cancer       Date:  2010-06-17       Impact factor: 27.401

10.  Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.

Authors:  Gérald J Prud'homme; Yelena Glinka; Anna Toulina; Olga Ace; Venkateswaran Subramaniam; Serge Jothy
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.